Disclosures for "Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias")
-
Ms. Rindner has nothing to disclose.
-
Ms. Mahdavi has nothing to disclose.
-
Mr. Haroon has nothing to disclose.
-
Ms. Jordan has nothing to disclose.
-
Ms. Zielinski has nothing to disclose.
-
Ms. Venkatraman has nothing to disclose.
-
Mr. Surya has nothing to disclose.
-
Dr. Goodenowe has stock in Prodrome Sciences USA LLC..
-
Mr. Ahlem has received personal compensation for serving as an employee of Biovie, Inc.. Mr. Ahlem has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Biovie, Inc.. Mr. Ahlem has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Reading has received personal compensation for serving as an employee of Biovie, Inc.. Dr. Reading has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Palumbo has received personal compensation for serving as an employee of BioVie. An immediate family member of Dr. Palumbo has received personal compensation for serving as an employee of Merck Research Laboratories. Dr. Palumbo has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for BioVie. Dr. Palumbo has stock in BioVie. An immediate family member of Dr. Palumbo has stock in Merck Research Laboratories. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. POURAT has nothing to disclose.
-
Dr. Jordan has stock in Synaptec Network.